Crinetics Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	3,282	2,377	985	1,349	465	608	721	-	-
Market Cap Growth	-	141.36%	-27.03%	190.50%	-23.56%	-15.69%	-	-	-
Enterprise Value	2,774	1,869	652	1,018	297	494	556	-14	-12
PE Ratio	-11.08	-11.08	-6.01	-12.54	-6.29	-12.05	-26.59	-	-
PS Ratio	817.94	592.26	207.88	1251.83	6542.73	509.42	296.90	-	-
PB Ratio	6.09	4.41	3.11	4.07	2.75	5.19	4.50	-	-
P/FCF Ratio	-13.90	-13.90	-8.43	-15.16	-7.47	-12.97	-35.13	-	-
P/OCF Ratio	-14.29	-14.29	-8.55	-15.23	-7.49	-13.10	-37.05	-	-
EV/Sales Ratio	691.32	465.63	137.66	944.66	4185.47	413.83	229.20	-6.94	-20.27
EV/EBITDA Ratio	-8.80	-8.80	-4.01	-9.57	-4.09	-10.01	-20.89	1.57	2.02
EV/EBIT Ratio	-8.71	-8.71	-3.98	-9.46	-4.03	-9.79	-20.52	1.55	1.99
EV/FCF Ratio	-10.93	-10.93	-5.58	-11.44	-4.78	-10.53	-27.12	1.45	2.11
Debt / Equity Ratio	0.10	0.10	0.01	0.01	0.02	0.04	-	-	-0.03
Debt / EBITDA Ratio	-0.24	-0.24	-0.02	-0.03	-0.06	-0.10	-	-	-0.04
Debt / FCF Ratio	-0.30	-0.30	-0.03	-0.03	-0.06	-0.10	-	-	-0.04
Quick Ratio	12.74	12.74	12.11	20.89	16.34	14.26	20.74	15.82	13.65
Current Ratio	13.07	13.07	12.45	21.55	16.92	14.79	21.03	16.91	13.89
Asset Turnover	0.01	0.01	0.01	0.01	0	0.01	0.02	0.14	-
Interest Coverage	-	-	-	-	-	-	-	-	-546.18
Return on Equity (ROE)	-52.90%	-52.90%	-48.30%	-49.10%	-44.20%	-37.30%	-38.40%	86.30%	-
Return on Assets (ROA)	-45.50%	-45.50%	-43.90%	-45.80%	-40.70%	-33.90%	-21.70%	-65.00%	-
Return on Capital (ROIC)	-37.68%	-37.68%	-52.56%	-32.15%	-43.34%	-44.13%	-17.92%	60.76%	100.87%
Earnings Yield	-6.54%	-9.03%	-16.65%	-7.98%	-15.89%	-8.30%	-3.76%	-	-
FCF Yield	-5.21%	-7.19%	-11.87%	-6.60%	-13.39%	-7.71%	-2.85%	-	-
Buyback Yield / Dilution	-11.71%	-11.71%	-35.24%	-26.23%	-25.95%	-99.10%	-785.63%	-35.61%	-
Total Shareholder Return	-11.71%	-11.71%	-35.24%	-26.23%	-25.95%	-99.10%	-785.63%	-35.61%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).